Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Supreme Court declines to hear Omnicef patent case

This article was originally published in Scrip

Executive Summary

The US Supreme Court has declined to hear Astellas Pharma's case against generic drug makers for allegedly infringing a patent for the cephalosporin antibiotic Omnicef (cefdinir), according to the legal site Having the high court decline a bid for certiorari is not unusual, as the court does not hear many patent cases. Generic drug makers Teva Pharmaceutical Industries, Novartis's Sandoz unit and Lupin all urged the justices not to hear the case.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts